Abstract
Adenosine is thought to be a neuromodulator or neurotransmitter in the mammalian peripheral tissues and central nervous systems and involved in biological events in mammalian tissues via specific interactions with G-protein-coupled adenosine receptors. Adenosine receptors are classified into four subtypes: A1, A2A, A2B, and A3. In the central nervous system (CNS), adenosine A2A receptors have a selective localization to the basal ganglia in contrast to other adenosine receptor subtypes and as a consequence offer a unique opportunity to modulate the output from the striatum that is believed critical to the occurrence of motor components of Parkinson’s disease (PD). Adenosine A2A receptor antagonists are active in predictive experimental models of PD and appear to be promising as a major non-dopaminergic therapy for PD. Istradefylline is the first adenosine A2A receptor antagonist approved for the treatment of PD and is currently only available in Japan, with the indication of “Improvement of ‘wearing off’ phenomena in patients with PD on concomitant treatment with l-DOPA containing products.” In this literature review, we will summarize the current knowledge from both clinical and nonclinical studies on the effects of adenosine A2A receptor blockade on PD. Also, we will summarize the potential feature aspects of the adenosine A2A receptor antagonist on the CNS functions.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Similar content being viewed by others
References
Aoyama S, Kase H, Borrelli E. Rescue of locomotor impairment in dopamine D2 receptor-deficient mice by an adenosine A2A receptor antagonist. J Neurosci. 2000;20:5848–52.
Augood SJ, Emson PC. Adenosine A2a receptor mRNA is expressed by enkephalin cells but not by somatostatin cells in rat striatum: a co-expression study. Brain Res Mol Brain Res. 1994;22:204–10.
Barzilai A, Melamed E. Molecular mechanisms of selective dopaminergic neuronal death in Parkinson’s disease. Trends Mol Med. 2003;9:126–32.
Basheer R, Strecker RE, Thakkar MM, McCarley RW. Adenosine and sleep–wake regulation. Prog Neurobiol. 2004;73:379–96.
Bonuccelli U. Comparing dopamine agonists in Parkinson’s disease. Curr Opin Neurol. 2003; 16(Suppl 1):S13–9.
Brooks DJ, Doder M, Osman S, Luthra SK, Hirani E, Hume S, et al. Positron emission tomography analysis of [11C]KW-6002 binding to human and rat adenosine A2A receptors in the brain. Synapse. 2008;62:671–81.
Chen JF. Adenosine receptor control of cognition in normal and disease. Int Rev Neurobiol. 2014;119:257–307.
DeLong M. Primate models of movement disorders of basal ganglia origin. Trends Neurosci. 1990;13:281–5.
Doyle TP, Lutz RS, Pellegrino JK, Sanders DJ, Arent SM. The effects of caffeine on arousal, response time, accuracy, and performance in division I collegiate fencers. J Strength Cond Res. 2016;30:3228–35.
El Yacoubi M, Ledent C, Parmentier M, Bertorelli R, Ongini E, Costentin J. Adenosine A2A receptor antagonists are potential antidepressants: evidence based on pharmacology and A2A receptor knockout mice. Br J Pharmacol. 2001;134:68–77.
El Yacoubi M, Costentin J, Vaugeois JM. Adenosine A2A receptors and depression. Neurology. 2003;61:S82–7.
Fahn S. Description of Parkinson’s disease as a clinical syndrome. Ann N Y Acad Sci. 2003;991:1–14.
Fahn S, Oakes D, Shoulson I, Kieburtz K, Rudolph A, Lang A. Levodopa and the progression of Parkinson’s disease. N Engl J Med. 2004;351:2498–508.
Ferré S, Rubio A, Fuxe K. Stimulation of adenosine A2 receptors induces catalepsy. Neurosci Lett. 1991;130:162–4.
Fredholm BB, IJzerman AP, Jacobson KA, Linden J, Muller CE. International Union of Pharmacology. XXV. Nomenclature and classification of adenosine receptors. Pharmacol Rev. 2001;53:527–52.
Grondin R, Bedard PJ, Hadj Tahar A, Gregoire L, Mori A, Kase H. Antiparkinsonian effect of a new selective adenosine A2A receptor antagonist in MPTP-treated monkeys. Neurology. 1999;52:1673–7.
Hauser RA, Hubble JP, Truong DD, Istradefylline US-001 Study Group. Randomized trial of the adenosine A2A receptor antagonist istradefylline in advanced PD. Neurology. 2003;61:297–303.
Hauser RA, Shulman LM, Trugman JM, Roberts JW, Mori A, Ballerini R, et al. Study of istradefylline in patients with Parkinson’s disease on levodopa with motor fluctuations. Mov Disord. 2008;23:2177–85.
Huang ZL, Qu WM, Eguchi N, Chen J-F, Schwarzschild MA, Fredholm BB, et al. Adenosine A2A, but not A1, receptors mediate the arousal effect of caffeine. Nat Neurosci. 2005;8:858–9.
Huang Z, Zhang Z, Qu WM. Roles of adenosine and its receptors in sleep-wake regulation. Int Rev Neurobiol. 2014;119:349–71.
Jacobson KA, Gao Z-G. Adenosine receptors as therapeutic targets. Nat Rev Drug Discov. 2006;5:247–64.
Kadowaki-Horita T, Kobayashi M, Mori A, Jenner P, Kanda T. Effects of the adenosine A2A antagonist istradefylline on cognitive performance in rats with a 6-OHDA lesion in prefrontal cortex. Psychopharmacology. 2013;230:345–52.
Kanda T, Shiozaki S, Shimada J, Suzuki F, Nakamura J. KF17837: a novel selective adenosine A2A receptor antagonist with anticataleptic activity. Eur J Pharmacol. 1994;256:263–8.
Kanda T, Jackson MJ, Smith LA, Pearce RKB, Nakamura J, Kase H, et al. Adenosine A2A antagonist: a novel antiparkinsonian agent that does not provoke dyskinesia in parkinsonian monkeys. Ann Neurol. 1998a;43:507–13.
Kanda T, Tashiro T, Kuwana Y, Jenner P. Adenosine A2A receptors modify motor function in MPTP-treated common marmosets. Neuroreport. 1998b;9:2857–60.
Koga K, Kurokawa M, Ochi M, Nakamura J, Kuwana Y. Adenosine A2A receptor antagonists KF17837 and KW-6002 potentiate rotation induced by dopaminergic drugs in hemi-parkinsonian rats. Eur J Pharmacol. 2000;408:249–55.
LeWitt PA, Guttman M, Tetrud JW, Tuite PJ, Mori A, Chaikin P, et al. Adenosine A2A receptor antagonist istradefylline (KW-6002) reduces “off” time in Parkinson’s disease: a double-blind, randomized, multicenter clinical trial (6002-US-005). Ann Neurol. 2008;63:295–302.
Matsuura K, Kajikawa H, Tabei K, Satoh M, Kida H, Nakamura N, et al. The effectiveness of istradefylline for the treatment of gait deficits and sleepiness in patients with Parkinson’s disease. Neurosci Lett. 2018;662:158–61.
McCarley RW. Neurobiology of REM and NREM sleep. Sleep Med. 2007;8:302–30.
Mizuno Y, Hasegawa K, Kondo T, Kuno S, Yamamoto M, et al. Clinical efficacy of istradefylline (KW-6002) in Parkinson’s disease: a randomized, controlled study. Mov Disord. 2010; 25:1437–43.
Mizuno Y, Kondo T, The Japanese Istradefylline Study Group. Adenosine A2A receptor antagonist Istradefylline reduces daily OFF time in Parkinson’s disease. Mov Disord. 2013;28:1138–41.
Mori A, Shindou T. Modulation of GABAergic transmission in the striatopallidal system by adenosine A2A receptors: a potential mechanism for the antiparkinsonian effects of A2A antagonists. Neurology. 2003;61(Suppl 6):S44–8.
Mori A, Shindou T, Ichimura M, Nonaka H, Kase H. The role of adenosine A2a receptors in regulating GABAergic synaptic transmission in striatal medium spiny neurons. J Neurosci. 1996;16:605–11.
Nomoto M, Nagai M, Nishikawa N. Clinical nonmotor aspect of A2A antagonist in PD treatment. Int Rev Neurobiol. 2014;119:191–4.
Porkka-Heiskanen T, Strecker RE, Thakkar M, Bjorkum AA, Greene RW, McCarley RW. Adenosine: a mediator of the sleep-inducing effects of prolonged wakefulness. Science. 1997;276:1265–8.
Pourcher M, Fernandez HH, Stacy M, Mori A, Ballerini R, Chaikin P. Istradefylline for Parkinson’s disease patients experiencing motor fluctuations: results of the KW-6002-US-018 study. Parkinsonism Relat Disord. 2012;18:178–84.
Saki M, Yamada K, Koshimura E, Sasaki K, Kanta T. In vitro pharmacological profile of the A2A receptor antagonist istradefylline. Naunyn Schmiedebergs Arch Pharmacol. 2013;386:963–72.
Shindou T, Mori A, Kase H, Ichimura M. Adenosine A2A receptor enhances GABAA-mediated IPSCs in the rat globus pallidus. J Physiol. 2001;532:423–34.
Shiozaki S, Ichikawa S, Nakamura J, Kitamura S, Yamada K, Kuwana Y. Actions of adenosine A2A receptor antagonist KW-6002 on drug-induced catalepsy and hypokinesia caused by reserpine or MPTP. Psychopharmacology. 1999;147:90–5.
Stacy M, Silver D, Mendis T, Sutton J, Mori A, Chaikin P, et al. A 12-week, placebo-controlled study (6002-US-006) of istradefylline in Parkinson disease. Neurology. 2008;70:2233–40.
Suzuki K, Miyamoto M, Miyamoto T, Uchiyama T, Watanabe Y, Suzuki S, et al. Istradefylline improves daytime sleepiness in patients with Parkinson’s disease: an open-label, 3-month study. J Neurol Sci. 2017;380:230–3.
Takahashi RN, Pamplona FA, Prediger RD. Adenosine receptor antagonists for cognitive dysfunction: a review of animal studies. Front Biosci. 2008;13:2614–32.
Uchida S, Tashiro T, Kawai-Uchida M, Mori A, Jenner P, Kanda T. The adenosine A2A-receptor antagonist Istradefylline enhances the motor response of l-DOPA without worsening dyskinesia in MPTP-treated common marmosets. J Pharmacol Sci. 2014;124:480–5.
Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, et al. The adenosine A2A receptor antagonist, istradefylline enhances the anti-parkinsonian activity of low doses of dopamine agonists in MPTP-treated common marmosets. Eur J Pharmacol. 2015a;747:160–5.
Uchida S, Soshiroda K, Okita E, Kawai-Uchida M, Mori A, Jenner P, et al. The adenosine A2A receptor antagonist, istradefylline enhances anti-parkinsonian activity induced by combined treatment with low doses of l-DOPA and dopamine agonists in MPTP-treated common marmosets. Eur J Pharmacol. 2015b;766:25–30.
Yamada K, Kobayashi M, Mori A, Jenner P, Kanda T. Antidepressant-like activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002), in the forced swim test and the tail suspension test in rodents. Pharmacol Biochem Behav. 2013;114–115:23–30.
Yamada K, Kobayashi M, Shiozaki S, Ohta T, Mori A, Jenner P, et al. Antidepressant activity of the adenosine A2A receptor antagonist, istradefylline (KW-6002) on learned helplessness in rats. Psychopharmacology. 2014;231:2839–49.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this entry
Cite this entry
Kanda, T., Nomoto, M. (2022). Istradefylline for Treating Parkinson’s Disease. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-030-62059-2_361
Download citation
DOI: https://doi.org/10.1007/978-3-030-62059-2_361
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-62058-5
Online ISBN: 978-3-030-62059-2
eBook Packages: MedicineReference Module Medicine